Status and phase
Conditions
Treatments
About
This study is designed to evaluate the efficacy and the safety of Trafermin(recombinant human basic fibroblast growth factor: rhbFGF) in Japanese patients with marginal periodontitis, in order to verify the superiority of Trafermin to placebo, and to determine the recommended therapeutic dose.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
The patient with marginal periodontitis intend to conduct a flap operation(modified Widman) must meet the following criteria:
Exclusion criteria
Patients will be excluded from the study if any of the following conditions are present:
Primary purpose
Allocation
Interventional model
Masking
267 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal